Compare OCGN & JFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OCGN | JFIN |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 387.3M | 330.9M |
| IPO Year | N/A | 2019 |
| Metric | OCGN | JFIN |
|---|---|---|
| Price | $1.60 | $6.92 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 6.2M | 88.9K |
| Earning Date | 03-04-2026 | 11-25-2025 |
| Dividend Yield | N/A | ★ 11.54% |
| EPS Growth | N/A | ★ 50.48 |
| EPS | N/A | ★ 4.56 |
| Revenue | $5,370,000.00 | ★ $918,148,810.00 |
| Revenue This Year | $35.88 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1.52 |
| Revenue Growth | ★ 14.26 | 8.99 |
| 52 Week Low | $0.52 | $5.73 |
| 52 Week High | $1.96 | $19.23 |
| Indicator | OCGN | JFIN |
|---|---|---|
| Relative Strength Index (RSI) | 51.18 | 53.13 |
| Support Level | $1.47 | $6.87 |
| Resistance Level | $1.70 | $7.10 |
| Average True Range (ATR) | 0.14 | 0.30 |
| MACD | -0.02 | 0.07 |
| Stochastic Oscillator | 21.43 | 68.35 |
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
Jiayin Group Inc is China's technology service group. It is an enterprise engaged in technological innovation services. It is committed to using big data, cloud computing, artificial intelligence and other technologies to connect consumers and financial institutions in consumption scenarios so that every user can enjoy efficient and convenient technology services. The company has engraved technological innovation into the company's development genes since its establishment, adheres to the dual drive of digital plus technology, and focuses on building a cloud service platform and intelligent risk control system with big data drive as the core concept.